Rémi Droller
MANAGING PARTNER
Management
Kurma Partners
Denmark
Biography
Master in Molecular Biology (Paris VI) and Master in Finance and Innovation Management (Masternova - AgroPariTech). Started at CDC Innovation from 2000 to 2003, later joining AGF Private Equity (now Idinvest Partners) where he developed the investment activity in the life sciences and made investments such as Novagali Pharma (listed on Euronext and acquired by Santen) Prosensa Therapeutics (listed on Nasdaq and acquired by Biomarin) Vivacta (acquired by Novartis), IntegraGen (listed on Alternext) Onxeo (listed on Euronext). Rémi joined Kurma Partners in 2010 and is in charge of investments in AM Pharma (The Netherlands), Orphazyme (Denmark), Oxthera (Sweden), Stat Diagnostica (Spain), Zealand Pharma (Denmark) and Dynacure (France).
Research Interest
Biomedical science, Business management, Molecular Biology
